Get the Stockscreener App
1.54
2.67%
0.04
Neurosense Therapeutics Ltd Stock (NRSN) Forecast
The Neurosense Therapeutics Ltd (NRSN) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $0.9204, representing a -40.23% decrease from the current price of $1.54. The highest analyst price target is $1.7743, and the lowest is $0.0665.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month NRSN Price Target
Average 0.892
(-42.08% Downside)
Is Neurosense Therapeutics Ltd (NRSN) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 66.76 | Neutral |
| STOCH(9,6) | 75.63 | Neutral |
| STOCHRSI(14) | 26.60 | Neutral |
| MACD(12,26) | 0.1342 | Buy |
| ADX(14) | 37.98 | Buy |
| William %R | -17.95 | Sell |
| CCI(14) | 36.30 | Neutral |
Buy: 2
Sell: 1
Neutral: 4
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
1.494
Buy
|
1.4645
Buy
|
| MA20 |
1.301
Buy
|
1.3519
Buy
|
| MA50 |
1.1248
Buy
|
1.2077
Buy
|
| MA100 |
1.1187
Buy
|
1.152
Buy
|
| MA200 |
1.1144
Buy
|
1.1512
Buy
|
Buy: 10
Sell: 0
Neutral: 0
Summary: Buy
According to our latest analysis, NRSN could be considered a Strong Buy, with 17 technical analysis indicators signaling 12 Buy signals, 1 signaling Sell signals and 4 Neutral signals. This might be a good time to open fresh positions on NRSN, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 66.76 indicates that NRSN is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 75.63 indicates that NRSN is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 26.6 indicates that NRSN is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 37.98 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 36.3 indicates that NRSN is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term NRSN price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Neurosense Therapeutics Ltd financial reports and earnings history, Neurosense Therapeutics Ltd (NRSN) stock could reach $2.6542 by 2030, $3.3886 by 2040 and $8.2609 by 2050. See the projected annual prices until 2050 of the Neurosense Therapeutics Ltd stock below:
- Neurosense Therapeutics Ltd (NRSN) is expected to reach an average price of $5.5438 in 2035, with a high prediction of $5.3357 and a low estimate of $4.94. This indicates an $259.99% rise from the last recorded price of $1.54.
- Neurosense Therapeutics Ltd (NRSN) stock is projected to chart a bullish course in 2040, with an average price target of $3.214, representing an $108.70% surge from its current level. The forecast ranges from a conservative $3.4388 to a sky-high $3.3886.
- Our analysts predict Neurosense Therapeutics Ltd (NRSN) to jump 316.03% by 2045, soaring from $6.4719 to an average price of $6.4069, potentially reaching $6.4822. While $6.4719 is the low estimate, the potential upside is significant.
- Neurosense Therapeutics Ltd (NRSN) stock is expected to climb by 2050, reaching an average of $8.3447, a $441.87% jump from its current level. However, a wide range of estimates exists, with high and low targets of $8.2609 and $8.3528, respectively, highlighting the market's uncertainty.
Neurosense Therapeutics Ltd Stock (NRSN) Year by Year Forecast
Neurosense Therapeutics Ltd Stock (NRSN) Price Forecast for 2025
Neurosense Therapeutics Ltd Stock (NRSN) is expected to reach an average price of $0.8887 in 2025, with a high prediction of $1.7743 and a low estimate of $0.00314. This indicates an -42.29% fall from the last recorded price of $1.54.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| July, 2025 | $0.5117 | $0.0665 | $1.7743 | -66.77% |
| August, 2025 | $0.7649 | $0.3775 | $0.9549 | -50.33% |
| September, 2025 | $0.6682 | $0.4624 | $0.7708 | -56.61% |
| October, 2025 | $0.9772 | $0.4598 | $1.1272 | -36.54% |
| November, 2025 | $0.5804 | $0.5604 | $1.113 | -62.31% |
| December, 2025 | $0.5695 | $0.3105 | $1.1579 | -63.02% |
Neurosense Therapeutics Ltd Stock (NRSN) Price Forecast for 2026
The predicted value for Neurosense Therapeutics Ltd (NRSN) in 2026 is set at an average of $0.7965. Estimates vary from a peak of $1.5834 to a trough of $0.00966, indicating an -48.28% surge from the present price of $1.54.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $0.4027 | $0.3153 | $0.6253 | -73.85% |
| February, 2026 | $0.00175 | $0.00966 | $0.4835 | -99.89% |
| March, 2026 | $0.000318 | $0.0566 | $0.1218 | -99.98% |
| April, 2026 | $0.2862 | $0.085 | $0.0677 | -81.42% |
| May, 2026 | $0.4079 | $0.376 | $0.396 | -73.51% |
| June, 2026 | $0.2032 | $0.3751 | $0.3628 | -86.80% |
| July, 2026 | $0.0406 | $0.0662 | $0.6721 | -97.37% |
| August, 2026 | $0.167 | $0.0289 | $0.167 | -89.16% |
| September, 2026 | $0.606 | $0.093 | $0.636 | -60.65% |
| October, 2026 | $1.0492 | $0.3924 | $1.5834 | -31.87% |
| November, 2026 | $0.9825 | $0.575 | $1.5325 | -36.20% |
| December, 2026 | $0.8136 | $0.4099 | $1.2173 | -47.17% |
Neurosense Therapeutics Ltd Stock (NRSN) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Neurosense Therapeutics Ltd (NRSN) is $2.7005, with a high forecast of $5.3394 and a low forecast of $0.0615. This indicates an +75.35% increase from the last price of $1.54.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $0.9752 | $0.47 | $0.918 | -36.68% |
| February, 2027 | $1.3887 | $1.2019 | $1.2437 | -9.83% |
| March, 2027 | $1.3794 | $0.8106 | $5.3394 | -10.43% |
| April, 2027 | $0.7741 | $0.2358 | $2.371 | -49.73% |
| May, 2027 | $1.4777 | $0.9277 | $1.1977 | -4.05% |
| June, 2027 | $1.2296 | $1.3128 | $1.2862 | -20.16% |
| July, 2027 | $0.6569 | $0.3348 | $1.8152 | -57.35% |
| August, 2027 | $0.7267 | $0.0615 | $0.6485 | -52.81% |
| September, 2027 | $0.5886 | $0.6186 | $0.4886 | -61.78% |
| October, 2027 | $0.8921 | $0.5854 | $0.467 | -42.07% |
| November, 2027 | $0.8957 | $0.8089 | $0.6657 | -41.84% |
| December, 2027 | $0.538 | $0.8376 | $0.8224 | -65.07% |
Neurosense Therapeutics Ltd Stock (NRSN) Price Forecast for 2028
In 2028, Neurosense Therapeutics Ltd (NRSN) is projected to reach an average price of $0.5752, with a high projection of $0.9863 and a low estimate of $0.1642. This indicates an -62.65% fall from the last price of $1.54.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $0.7611 | $0.716 | $0.6227 | -50.58% |
| February, 2028 | $1.034 | $0.9719 | $0.9863 | -32.86% |
| March, 2028 | $0.6066 | $0.7098 | $0.933 | -60.61% |
| April, 2028 | $0.3301 | $0.3901 | $0.345 | -78.56% |
| May, 2028 | $0.412 | $0.4784 | $0.382 | -73.24% |
| June, 2028 | $0.0656 | $0.2656 | $0.3588 | -95.74% |
| July, 2028 | $0.4391 | $0.3707 | $0.2991 | -71.49% |
| August, 2028 | $0.421 | $0.1642 | $0.4274 | -72.66% |
| September, 2028 | $0.5646 | $0.6146 | $0.4762 | -63.34% |
| October, 2028 | $0.9423 | $0.6613 | $0.7981 | -38.81% |
| November, 2028 | $0.953 | $0.9816 | $0.8849 | -38.12% |
| December, 2028 | $1.178 | $1.0284 | $0.9653 | -23.51% |
Neurosense Therapeutics Ltd Stock (NRSN) Price Forecast for 2029
The 2029 price forecast for Neurosense Therapeutics Ltd Stock (NRSN) is $1.9612 on average, with a high prediction of $3.9191 and a low estimate of $0.00331. This represents an +27.35% increase from the previous price of $1.54.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $1.2305 | $1.2619 | $1.2646 | -20.10% |
| February, 2029 | $0.389 | $1.029 | $1.1322 | -74.74% |
| March, 2029 | $0.8568 | $0.729 | $0.7724 | -44.36% |
| April, 2029 | $0.6261 | $0.7361 | $0.8009 | -59.35% |
| May, 2029 | $0.158 | $0.3595 | $0.4845 | -89.74% |
| June, 2029 | $0.3085 | $0.2385 | $0.8368 | -79.97% |
| July, 2029 | $0.2649 | $0.00331 | $0.8149 | -82.80% |
| August, 2029 | $0.296 | $0.0865 | $0.5055 | -80.78% |
| September, 2029 | $2.4477 | $1.96 | $2.3905 | +58.94% |
| October, 2029 | $1.7306 | $2.5706 | $2.693 | +12.38% |
| November, 2029 | $0.0409 | $2.2309 | $3.9191 | -97.34% |
| December, 2029 | $2.1712 | $0.5361 | $1.4012 | +40.99% |
Neurosense Therapeutics Ltd Stock (NRSN) Price Forecast for 2030
Neurosense Therapeutics Ltd Stock (NRSN) is expected to reach an average price of $1.6995 in 2030, with a high forecast of $2.6542 and a low forecast of $0.7447. This signifies an +10.35% surge from the last price of $1.54.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $2.6941 | $2.319 | $2.6542 | +74.94% |
| February, 2030 | $2.5744 | $2.6644 | $2.5667 | +67.17% |
| March, 2030 | $0.6647 | $0.7447 | $2.307 | -56.84% |
| April, 2030 | $2.025 | $1.3773 | $1.8679 | +31.49% |
| May, 2030 | $1.8579 | $1.8879 | $1.7603 | +20.64% |
| June, 2030 | $2.1382 | $1.843 | $1.7305 | +38.84% |
| July, 2030 | $2.1311 | $2.0433 | $1.9811 | +38.38% |
| August, 2030 | $1.7318 | $2.0314 | $2.0337 | +12.45% |
| September, 2030 | $1.9317 | $1.8991 | $1.7991 | +25.43% |
| October, 2030 | $2.0746 | $2.1367 | $2.1394 | +34.71% |
| November, 2030 | $1.7249 | $1.8397 | $1.7123 | +12.00% |
| December, 2030 | $1.4252 | $1.4852 | $1.4574 | -7.46% |
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):